Later-Line Combination Therapies Used as Treatment in Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their choice of combination therapy after disease relapse of multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.

Douglas Sborov, MD, MS, discusses and compares the many triplet therapies for patients who show disease progression after several lines of therapy in this first article of a 2 part series.

In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.

In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.

In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.

In the second article of a 2-part series, Douglas Sborov, MD, discusses the toxicities seen with isatuximab and how this therapy can impact patients in rural areas relying on community center treatment.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.